US6777217B1
(en)
|
1996-03-26 |
2004-08-17 |
President And Fellows Of Harvard College |
Histone deacetylases, and uses related thereto
|
US6822267B1
(en)
*
|
1997-08-20 |
2004-11-23 |
Advantest Corporation |
Signal transmission circuit, CMOS semiconductor device, and circuit board
|
KR20020070285A
(ko)
|
1999-11-23 |
2002-09-05 |
메틸진, 인크. |
히스톤 디아세틸라제의 억제제
|
US20030129724A1
(en)
|
2000-03-03 |
2003-07-10 |
Grozinger Christina M. |
Class II human histone deacetylases, and uses related thereto
|
PE20020354A1
(es)
*
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
EP1335898B1
(en)
|
2000-09-29 |
2005-11-23 |
TopoTarget UK Limited |
Carbamic acid compounds comprising an amide linkage as hdac inhibitors
|
US7312247B2
(en)
*
|
2001-03-27 |
2007-12-25 |
Errant Gene Therapeutics, Llc |
Histone deacetylase inhibitors
|
WO2003032921A2
(en)
*
|
2001-10-16 |
2003-04-24 |
Sloan-Kettering Institute For Cancer Research |
Treatment of neurodegenerative diseases and cancer of the brain
|
BR0213932A
(pt)
*
|
2001-11-06 |
2004-08-31 |
Novartis Ag |
Combinação do inibidor da ciclooxigenase-2/inibidor da desacetilase histona
|
CA2632078C
(en)
|
2002-03-04 |
2012-08-14 |
Sloan-Kettering Institute For Cancer Research |
Methods of inducing terminal differentiation
|
US7148257B2
(en)
|
2002-03-04 |
2006-12-12 |
Merck Hdac Research, Llc |
Methods of treating mesothelioma with suberoylanilide hydroxamic acid
|
US7456219B2
(en)
|
2002-03-04 |
2008-11-25 |
Merck Hdac Research, Llc |
Polymorphs of suberoylanilide hydroxamic acid
|
ATE399012T1
(de)
|
2002-04-03 |
2008-07-15 |
Topotarget Uk Ltd |
Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren
|
WO2003087066A1
(en)
*
|
2002-04-11 |
2003-10-23 |
Sk Chemicals, Co., Ltd. |
α,β-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
|
AU2003226408B2
(en)
*
|
2002-04-15 |
2007-06-14 |
Sloan-Kettering Institute For Cancer Research |
Combination therapy for the treatment of cancer
|
EP2179745A1
(en)
*
|
2002-06-10 |
2010-04-28 |
Novartis AG |
Combinations comprising epothilones and pharmaceutical uses thereof
|
EP1547617B1
(en)
*
|
2002-08-20 |
2010-04-28 |
Astellas Pharma Inc. |
Arthrodial cartilage extracellular matrix degradation inhibitor
|
ATE521354T1
(de)
*
|
2002-09-13 |
2011-09-15 |
Univ Virginia Commonwealth |
Kombination aus imatinib und einem histondeacetylase-hemmer zur behandlung von leukämie
|
US7154002B1
(en)
|
2002-10-08 |
2006-12-26 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
US7250514B1
(en)
|
2002-10-21 |
2007-07-31 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
EP1562898A1
(en)
*
|
2002-11-19 |
2005-08-17 |
Takeda Pharmaceutical Company Limited |
Indole derivatives as somatostatin agonists or antagonists
|
WO2004052292A2
(en)
|
2002-12-06 |
2004-06-24 |
University Of South Florida |
Histone deacetylase inhibitor enhancement of trail-induced apoptosis
|
TW200418806A
(en)
|
2003-01-13 |
2004-10-01 |
Fujisawa Pharmaceutical Co |
HDAC inhibitor
|
US7465719B2
(en)
|
2003-01-17 |
2008-12-16 |
Topotarget Uk Limited |
Carbamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors
|
AU2003900608A0
(en)
*
|
2003-02-11 |
2003-02-27 |
Fujisawa Pharmaceutical Co., Ltd. |
Hdac inhibitor
|
AU2003900587A0
(en)
*
|
2003-02-11 |
2003-02-27 |
Fujisawa Pharmaceutical Co., Ltd. |
Hdac inhibitor
|
US7652036B2
(en)
|
2003-02-25 |
2010-01-26 |
Topotarget Uk Limited |
Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors
|
EP1608628A2
(en)
|
2003-03-17 |
2005-12-28 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
WO2004103358A2
(en)
*
|
2003-05-21 |
2004-12-02 |
Novartis Ag |
Combination of histone deacetylase inhibitors with chemotherapeutic agents
|
WO2005011598A2
(en)
*
|
2003-07-31 |
2005-02-10 |
University Of South Florida |
Leukemia treatment method and composition
|
JP2007501775A
(ja)
*
|
2003-08-07 |
2007-02-01 |
ノバルティス アクチエンゲゼルシャフト |
免疫抑制剤としてのヒストンデアセチラーゼ阻害剤
|
JP2007501774A
(ja)
*
|
2003-08-08 |
2007-02-01 |
ノバルティス アクチエンゲゼルシャフト |
スタウロスポリンを含む組み合わせ
|
JP4338734B2
(ja)
|
2003-08-26 |
2009-10-07 |
メルク エイチディーエーシー リサーチ エルエルシー |
Hdac阻害剤による癌処置法
|
CN101856348A
(zh)
|
2003-08-29 |
2010-10-13 |
斯隆-凯特林癌症研究所 |
联合治疗癌症的方法
|
CN100455564C
(zh)
*
|
2003-09-12 |
2009-01-28 |
深圳微芯生物科技有限责任公司 |
组蛋白去乙酰化酶抑制剂及其药用制剂的制备和应用
|
CA2539000A1
(en)
*
|
2003-09-18 |
2005-03-24 |
Novartis Ag |
Combination of a histone deacetylase inhibitor with a death receptor ligand
|
BRPI0414581C1
(pt)
|
2003-09-22 |
2021-05-25 |
Mei Pharma Inc |
composto, composição farmacêutica compreendendo o referido composto e uso do referido composto
|
EP1673349B1
(en)
*
|
2003-09-22 |
2010-06-30 |
S*Bio Pte Ltd |
Benzimidazole derivatives: preparation and pharmaceutical applications
|
US20080085902A1
(en)
*
|
2003-09-23 |
2008-04-10 |
Guido Bold |
Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent
|
TW200524575A
(en)
*
|
2003-10-27 |
2005-08-01 |
S Bio Pte Ltd |
Biaryl linked hydroxamates: preparation and pharmaceutical applications
|
ES2562778T3
(es)
|
2003-12-02 |
2016-03-08 |
The Ohio State University Research Foundation |
Ácidos grasos de cadena corta unidos a motivos quelantes de Zn2+ como una clase novedosa de inhibidores de histona deacetilasa
|
EP1541549A1
(en)
*
|
2003-12-12 |
2005-06-15 |
Exonhit Therapeutics S.A. |
Tricyclic hydroxamate and benzaminde derivatives, compositions and methods
|
WO2005066151A2
(en)
*
|
2003-12-19 |
2005-07-21 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
US20050159470A1
(en)
*
|
2003-12-19 |
2005-07-21 |
Syrrx, Inc. |
Histone deacetylase inhibitors
|
US20050197336A1
(en)
*
|
2004-03-08 |
2005-09-08 |
Miikana Therapeutics Corporation |
Inhibitors of histone deacetylase
|
US7345043B2
(en)
*
|
2004-04-01 |
2008-03-18 |
Miikana Therapeutics |
Inhibitors of histone deacetylase
|
CN1964970B
(zh)
|
2004-04-07 |
2011-08-03 |
诺瓦提斯公司 |
Iap的抑制剂
|
AU2005274973A1
(en)
*
|
2004-07-19 |
2006-02-23 |
Merck Sharp & Dohme Corp. |
Histone deacetylase inhibitors
|
WO2006016680A1
(en)
*
|
2004-08-09 |
2006-02-16 |
Astellas Pharma Inc. |
Hydroxyamide compounds having activity as inhibitors of histone deacetylase (hdac)
|
ITMI20041869A1
(it)
|
2004-10-01 |
2005-01-01 |
Dac Srl |
Nuovi inibitori delle istone deacetilasi
|
US8242175B2
(en)
|
2004-10-01 |
2012-08-14 |
Dac S.R.L. |
Class of histone deacetylase inhibitors
|
US20070021612A1
(en)
*
|
2004-11-04 |
2007-01-25 |
University Of Notre Dame Du Lac |
Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
|
US7235688B1
(en)
|
2004-11-04 |
2007-06-26 |
University Of Notre Dame Du Lac |
Process for preparing histone deacetylase inhibitors and intermediates thereof
|
US7642275B2
(en)
*
|
2004-12-16 |
2010-01-05 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
JP2008530136A
(ja)
|
2005-02-14 |
2008-08-07 |
ミイカナ セラピューティクス インコーポレイテッド |
ヒストンデアセチラーゼの阻害剤として有用な縮合複素環化合物
|
US7666880B2
(en)
|
2005-03-21 |
2010-02-23 |
S*Bio Pte Ltd. |
Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications
|
WO2006102557A2
(en)
|
2005-03-22 |
2006-09-28 |
The President And Fellows Of Harvard College |
Treatment of protein degradation disorders
|
GB0509223D0
(en)
*
|
2005-05-05 |
2005-06-15 |
Chroma Therapeutics Ltd |
Enzyme inhibitors
|
GB0509225D0
(en)
|
2005-05-05 |
2005-06-15 |
Chroma Therapeutics Ltd |
Inhibitors of enzymatic activity
|
EP1896436A2
(en)
*
|
2005-05-11 |
2008-03-12 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
TWI365068B
(en)
|
2005-05-20 |
2012-06-01 |
Merck Sharp & Dohme |
Formulations of suberoylanilide hydroxamic acid and methods for producing same
|
AU2006270322A1
(en)
*
|
2005-07-14 |
2007-01-25 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
WO2007016532A2
(en)
*
|
2005-08-02 |
2007-02-08 |
Novartis Ag |
Mutations and polymorphisms of hdac4
|
HUE028025T2
(en)
|
2005-08-03 |
2016-11-28 |
Novartis Ag |
Use of Panobinostat HDAC inhibitor to treat myeloma
|
CN101282718A
(zh)
*
|
2005-08-10 |
2008-10-08 |
诺瓦提斯公司 |
脱乙酰酶抑制剂的使用方法
|
BRPI0614810A2
(pt)
*
|
2005-08-11 |
2009-08-04 |
Novartis Ag |
combinação de compostos orgánicos
|
CA2620333A1
(en)
|
2005-08-26 |
2007-03-01 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
JP2009509923A
(ja)
*
|
2005-08-26 |
2009-03-12 |
メシルジーン、インコーポレイテッド |
ヒストンデアセチラーゼのベンゾジアゼピン及びベンゾピペラジン類似体阻害薬
|
EP2258358A3
(en)
|
2005-08-26 |
2011-09-07 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
WO2007030455A2
(en)
*
|
2005-09-07 |
2007-03-15 |
Novartis Ag |
Mutations and polymorphisms of hdac10
|
WO2007030454A2
(en)
*
|
2005-09-07 |
2007-03-15 |
Novartis Ag |
Mutations and polymorphisms of hdac9
|
WO2007038073A2
(en)
*
|
2005-09-22 |
2007-04-05 |
Novartis Ag |
Mutations and polymorphisms of hdac11
|
AR058065A1
(es)
|
2005-09-27 |
2008-01-23 |
Novartis Ag |
Compuestos de carboxiamina y uso de los mismos.composiciones farmaceuticas.
|
EP1940389A2
(en)
|
2005-10-21 |
2008-07-09 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
WO2007047998A2
(en)
*
|
2005-10-21 |
2007-04-26 |
Novartis Ag |
Mutations and polymorphisms of hdac2
|
AU2006306240A1
(en)
|
2005-10-24 |
2007-05-03 |
Novartis Ag |
Combination of histone deacetylase inhibitors and radiation
|
CA2625210A1
(en)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
WO2007053502A2
(en)
*
|
2005-11-01 |
2007-05-10 |
Novartis Ag |
Mutations and polymorphisms of hdac5
|
WO2007058992A2
(en)
*
|
2005-11-14 |
2007-05-24 |
Novartis Ag |
Mutations and polymorphisms of hdac6
|
SI2275103T1
(sl)
|
2005-11-21 |
2014-07-31 |
Novartis Ag |
mTor inhibitorji pri zdravljenju endokrinih tumorjev
|
US20070207950A1
(en)
*
|
2005-12-21 |
2007-09-06 |
Duke University |
Methods and compositions for regulating HDAC6 activity
|
JP2009525955A
(ja)
*
|
2006-01-13 |
2009-07-16 |
タケダ サン ディエゴ インコーポレイテッド |
ヒストンデアセチラーゼ阻害剤
|
MX2008010035A
(es)
*
|
2006-02-07 |
2008-10-17 |
Astellas Pharma Inc |
Compuestos de n-hidroxiacrilamida.
|
JP5441416B2
(ja)
*
|
2006-02-14 |
2014-03-12 |
プレジデント アンド フェロウズ オブ ハーバード カレッジ |
二官能性ヒストンデアセチラーゼインヒビター
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
CA2645633A1
(en)
|
2006-04-05 |
2007-11-01 |
Novartis Ag |
Combinations of therapeutic agents for treating cancer
|
RU2452492C2
(ru)
|
2006-04-05 |
2012-06-10 |
Новартис Аг |
КОМБИНАЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ Bcr-Abl/c-Kit/PDGF-R TK, ДЛЯ ЛЕЧЕНИЯ РАКА
|
SI2450437T1
(sl)
|
2006-04-14 |
2017-12-29 |
Cell Signaling Technology Inc. |
Okvarjenost genov in mutantna ALK kinaza v človeških solidnih tumorjih
|
US8168383B2
(en)
|
2006-04-14 |
2012-05-01 |
Cell Signaling Technology, Inc. |
Gene defects and mutant ALK kinase in human solid tumors
|
EP2049139A4
(en)
|
2006-04-24 |
2009-06-24 |
Gloucester Pharmaceuticals Inc |
TREATMENT OF TUMORS EXPRESSING RAS
|
US20090018142A9
(en)
*
|
2006-05-02 |
2009-01-15 |
Zhengping Zhuang |
Use of phosphatases to treat tumors overexpressing N-CoR
|
MX2008014320A
(es)
|
2006-05-09 |
2009-03-25 |
Braincells Inc |
Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
|
AU2007249399A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
US20090317489A1
(en)
|
2006-05-09 |
2009-12-24 |
Hanspeter Nick |
Combination Comprising an Iron Chelator and an Anti-Neoplastic Agent and Use Thereof
|
US8957027B2
(en)
|
2006-06-08 |
2015-02-17 |
Celgene Corporation |
Deacetylase inhibitor therapy
|
PL2032531T3
(pl)
*
|
2006-06-12 |
2016-07-29 |
Novartis Ag |
Sole N-hydroksy-3-[4-[[[2-(2-metylo-1H-indol-3-ilo)etylo]amino]metylo]fenylo]-2E-2-propenoamidu
|
BRPI0713653A2
(pt)
*
|
2006-06-12 |
2012-10-23 |
Novartis Ag |
processo para a preparação de sais de n-hidróxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil ]fenil]-2e-2propenamida
|
CN102584673B
(zh)
*
|
2006-06-12 |
2014-08-06 |
诺华股份有限公司 |
N-羟基-3-[4-[[[2-(2-甲基-1h-吲哚-3-基)乙基]氨基]甲基]苯基]-2e-2-丙烯酰胺的多晶型物
|
CN101466672B
(zh)
*
|
2006-06-12 |
2012-05-16 |
诺瓦提斯公司 |
N-羟基-3-[4-[[[2-(2-甲基-1h-吲哚-3-基)乙基]氨基]甲基]苯基]-2e-2-丙烯酰胺的盐
|
EP2394991B1
(en)
*
|
2006-06-12 |
2015-09-23 |
Novartis AG |
Process for making starting materials for N-hydroxy-3-[4-[2-(2-methyl-1 H-indol-3-yl)-ethylaminomethyl]-phenyl]-2E-2-propenamide
|
CA2660782A1
(en)
*
|
2006-06-26 |
2008-01-03 |
Novartis Ag |
Organic compounds
|
MX2009002496A
(es)
|
2006-09-08 |
2009-07-10 |
Braincells Inc |
Combinaciones que contienen un derivado de 4-acilaminopiridina.
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
EP2064211B1
(en)
|
2006-09-20 |
2015-11-11 |
MEI Pharma, Inc. |
Imidazo[1,2-a]pyridine hydroxymate compounds that are inhibitors of histone deacetylase
|
CA2663614A1
(en)
*
|
2006-09-28 |
2008-04-10 |
Merck And Co., Inc. |
Amine base salts of saha and polymorphs thereof
|
AU2007302263A1
(en)
|
2006-09-29 |
2008-04-03 |
Novartis Ag |
Pyrazolopyrimidines as P13K lipid kinase inhibitors
|
GB0619753D0
(en)
|
2006-10-06 |
2006-11-15 |
Chroma Therapeutics Ltd |
Enzyme inhibitors
|
WO2008053131A1
(en)
|
2006-10-30 |
2008-05-08 |
Chroma Therapeutics Ltd. |
Hydroxamates as inhibitors of histone deacetylase
|
JP2010509370A
(ja)
*
|
2006-11-10 |
2010-03-25 |
シンダックス ファーマシューティカルズ,インク. |
癌の治療用のERα+リガンドとヒストンデアセチラーゼ阻害剤との組み合わせ
|
AU2007328281B2
(en)
*
|
2006-12-04 |
2011-03-31 |
Novartis Ag |
Combination of an HDAC inhibitor and an antimetabolite
|
MX2009006129A
(es)
*
|
2006-12-15 |
2009-06-18 |
Astellas Pharma Inc |
Compuestos de n-hidroxiacrilamida.
|
KR20090098920A
(ko)
*
|
2007-01-10 |
2009-09-17 |
노파르티스 아게 |
데아세틸라제 억제제의 제제
|
AU2008214299B2
(en)
|
2007-02-06 |
2014-01-09 |
Lixte Biotechnology, Inc. |
Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
|
EP2491923A3
(en)
|
2007-02-15 |
2012-12-26 |
Novartis AG |
Combinations of therapeutic agents for treating cancer
|
CA2680838A1
(en)
|
2007-03-28 |
2008-10-16 |
Santen Pharmaceutical Co., Ltd. |
Intraocular pressure-lowering agent comprising compound having histone deacetylase inhibitory effect as active ingredient
|
CN101679220A
(zh)
|
2007-04-09 |
2010-03-24 |
梅特希尔基因公司 |
组蛋白脱乙酰酶抑制剂
|
EP2142190A1
(en)
*
|
2007-05-04 |
2010-01-13 |
Novartis Ag |
Use of hdac inhibitors for the treatment of gastrointestinal cancers
|
TW200911231A
(en)
*
|
2007-05-11 |
2009-03-16 |
Novartis Ag |
Use of HDAC inhibitors for the treatment of melanoma
|
JP2010529028A
(ja)
*
|
2007-05-30 |
2010-08-26 |
ノバルティス アーゲー |
骨破壊の処置のためのhdac阻害剤の使用
|
US7737175B2
(en)
|
2007-06-01 |
2010-06-15 |
Duke University |
Methods and compositions for regulating HDAC4 activity
|
AU2008284364A1
(en)
*
|
2007-08-03 |
2009-02-12 |
Lixte Biotechnology, Inc. |
Use of phosphatases to treat neuroblastomas and medulloblastomas
|
CL2008002786A1
(es)
*
|
2007-09-20 |
2009-05-15 |
Novartis Ag |
Torta farmceuticamente aceptable, formada por liofilizacion, que comprende: n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il]-etil]-amino]-metil]-fenil]-2e-2-propenamida o una sal, un regulador de ph seleciondo de lactato o acidop lactico, fodfato o acido fosforico o una combinacion y un agente de volumen; proceso de elaboracion.
|
EA018618B1
(ru)
|
2007-10-01 |
2013-09-30 |
Ликсте Байотекнолоджи, Инк. |
Ингибиторы hdac
|
CN101896457A
(zh)
*
|
2007-10-22 |
2010-11-24 |
幽兰研究实验室有限公司 |
组蛋白脱乙酰基酶抑制剂
|
CN101417967A
(zh)
*
|
2007-10-26 |
2009-04-29 |
浙江海正药业股份有限公司 |
组蛋白去乙酰酶抑制剂、其组合物及其应用
|
US20090131367A1
(en)
*
|
2007-11-19 |
2009-05-21 |
The Regents Of The University Of Colorado |
Combinations of HDAC Inhibitors and Proteasome Inhibitors
|
CA2706750A1
(en)
*
|
2007-11-27 |
2009-06-04 |
Ottawa Health Research Institute |
Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors
|
AU2008350907A1
(en)
|
2007-12-11 |
2009-08-27 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
|
ITFI20070288A1
(it)
|
2007-12-21 |
2009-06-22 |
A I L Firenze Sezione Autonoma |
Inibitori delle deacetilasi istoniche
|
EP2100879A1
(en)
*
|
2008-03-13 |
2009-09-16 |
4Sc Ag |
Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds
|
EP2268612B1
(en)
|
2008-03-24 |
2014-08-20 |
Novartis AG |
Arylsulfonamide-based matrix metalloprotease inhibitors
|
CN102036955B
(zh)
*
|
2008-03-26 |
2013-03-27 |
诺瓦提斯公司 |
脱乙酰酶b的异羟肟酸盐为基础的抑制剂
|
JP2011528662A
(ja)
*
|
2008-07-18 |
2011-11-24 |
ノバルティス アーゲー |
ホジキン病の治療のためのhdac阻害剤の使用
|
US8440716B2
(en)
|
2008-07-23 |
2013-05-14 |
President And Fellows Of Harvard College |
Deacetylase inhibitors and uses thereof
|
US8227473B2
(en)
|
2008-08-01 |
2012-07-24 |
Lixte Biotechnology, Inc. |
Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
|
AU2009277179A1
(en)
*
|
2008-08-01 |
2010-02-04 |
Lixte Biotechnology, Inc. |
Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
|
CA2730148C
(en)
|
2008-08-01 |
2018-04-03 |
Lixte Biotechnology, Inc. |
Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
|
WO2010147612A1
(en)
|
2009-06-18 |
2010-12-23 |
Lixte Biotechnology, Inc. |
Methods of modulating cell regulation by inhibiting p53
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
WO2010088335A1
(en)
|
2009-01-29 |
2010-08-05 |
Novartis Ag |
Substituted benzimidazoles for the treatment of astrocytomas
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
GB0903480D0
(en)
*
|
2009-02-27 |
2009-04-08 |
Chroma Therapeutics Ltd |
Enzyme Inhibitors
|
KR101168801B1
(ko)
|
2009-03-27 |
2012-07-25 |
주식회사종근당 |
신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물
|
US7994357B2
(en)
|
2009-04-03 |
2011-08-09 |
Naturewise Biotech & Medicals Corporation |
Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
|
EP2236503B1
(en)
|
2009-04-03 |
2014-02-26 |
NatureWise Biotech & Medicals Corporation |
Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
|
EP2454267A2
(en)
|
2009-07-16 |
2012-05-23 |
Royal College of Surgeons in Ireland |
Metal complexes having dual histone deacetylase inhibitory and dna-binding activity
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
WO2011019393A2
(en)
*
|
2009-08-11 |
2011-02-17 |
President And Fellows Of Harvard College |
Class- and isoform-specific hdac inhibitors and uses thereof
|
BR112012003262A8
(pt)
|
2009-08-12 |
2016-05-17 |
Novartis Ag |
compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
|
CN105078978A
(zh)
|
2009-08-17 |
2015-11-25 |
因特利凯公司 |
杂环化合物及其用途
|
WO2011020861A1
(en)
|
2009-08-20 |
2011-02-24 |
Novartis Ag |
Heterocyclic oxime compounds
|
BR112012008075A2
(pt)
|
2009-08-26 |
2016-03-01 |
Novartis Ag |
compostos de heteroarila tetrassubstituídos e seu uso como moduladores de mdm2 e/ou mdm4
|
AR077975A1
(es)
|
2009-08-28 |
2011-10-05 |
Irm Llc |
Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
|
US20110053925A1
(en)
*
|
2009-08-28 |
2011-03-03 |
Novartis Ag |
Hydroxamate-Based Inhibitors of Deacetylases
|
EP2496575B1
(en)
|
2009-11-04 |
2014-04-30 |
Novartis AG |
Heterocyclic sulfonamide derivatives useful as mek inhibitors
|
BR112012012210B8
(pt)
|
2009-11-23 |
2021-05-25 |
Cerulean Pharma Inc |
conjugado de (cdp)-taxano de polímero contendo ciclodextrina, composição, composição farmacêutica, forma de dosagem, kit e uso de um conjugado de cdp-taxano
|
WO2011070030A1
(en)
|
2009-12-08 |
2011-06-16 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
US20130040998A1
(en)
*
|
2010-01-08 |
2013-02-14 |
Dana-Farber Cancer Institute, Inc. |
Fluorinated hdac inhibitors and uses thereof
|
WO2011088181A1
(en)
|
2010-01-13 |
2011-07-21 |
Tempero Pharmaceuticals, Inc. |
Compounds and methods
|
JP2013517281A
(ja)
|
2010-01-13 |
2013-05-16 |
テンペロ、ファーマシューティカルズ、インコーポレイテッド |
化合物及び方法
|
WO2011090940A1
(en)
|
2010-01-19 |
2011-07-28 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
UY33236A
(es)
|
2010-02-25 |
2011-09-30 |
Novartis Ag |
Inhibidores dimericos de las iap
|
WO2011119995A2
(en)
|
2010-03-26 |
2011-09-29 |
Cerulean Pharma Inc. |
Formulations and methods of use
|
US8217079B2
(en)
|
2010-03-26 |
2012-07-10 |
Italfarmaco Spa |
Method for treating Philadelphia-negative myeloproliferative syndromes
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
EP2407164A1
(en)
|
2010-07-14 |
2012-01-18 |
Dublin Institute of Technology Intellectual Property Ltd |
Copper II complexes of phenanthroline and their use in cancer treatment
|
WO2012025701A1
(en)
*
|
2010-08-25 |
2012-03-01 |
Chroma Therapeutics Ltd. |
Alpha, alpha - di substituted glycine ester derivatives and their use as hdac inhibitors
|
WO2012025155A1
(en)
*
|
2010-08-26 |
2012-03-01 |
Novartis Ag |
Hydroxamate-based inhibitors of deacetylases
|
JP2013536207A
(ja)
*
|
2010-08-27 |
2013-09-19 |
ノバルティス アーゲー |
ヒドロキサメート骨格のデアセチラーゼ類阻害剤
|
UY33794A
(es)
|
2010-12-13 |
2012-07-31 |
Novartis Ag |
Inhibidores diméricos de las iap
|
US20130266590A1
(en)
|
2010-12-13 |
2013-10-10 |
Novartis Ag |
Dimeric iap inhibitors
|
WO2012097013A1
(en)
|
2011-01-10 |
2012-07-19 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
TW201245115A
(en)
|
2011-01-24 |
2012-11-16 |
Chdi Foundation Inc |
Histone deacetylase inhibitors and compositions and methods of use thereof
|
US20130324526A1
(en)
|
2011-02-10 |
2013-12-05 |
Novartis Ag |
[1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
CN106619647A
(zh)
|
2011-02-23 |
2017-05-10 |
因特利凯有限责任公司 |
激酶抑制剂的组合及其用途
|
JP5808826B2
(ja)
|
2011-02-23 |
2015-11-10 |
インテリカイン, エルエルシー |
複素環化合物およびその使用
|
ES2842970T3
(es)
|
2011-03-09 |
2021-07-15 |
Cereno Scient Ab |
Compuestos y métodos para mejorar la fibrinólisis endógena alterada usando inhibidores de la histona desacetilasa
|
MX2013014398A
(es)
|
2011-06-09 |
2014-03-21 |
Novartis Ag |
Derivados de sulfonamida heterociclicos.
|
BR112013032125A2
(pt)
|
2011-06-14 |
2016-12-13 |
Novartis Ag |
combinação de panobinostat e ruxolitinibe no tratamento de câncer do tipo neoplasia mieloproliferativa
|
US8859586B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
US8859535B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
CN103608349A
(zh)
|
2011-06-27 |
2014-02-26 |
诺瓦提斯公司 |
四氢-吡啶并-嘧啶衍生物的固体形式和盐
|
CA2848809A1
(en)
|
2011-09-15 |
2013-03-21 |
Novartis Ag |
6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
|
CN108542906A
(zh)
|
2011-11-11 |
2018-09-18 |
诺华股份有限公司 |
治疗增生性疾病的方法
|
JP6216325B2
(ja)
|
2011-11-23 |
2017-10-18 |
ノバルティス アーゲー |
医薬製剤
|
CN103130673B
(zh)
*
|
2011-11-28 |
2017-05-03 |
重庆医药工业研究院有限责任公司 |
一种阿戈美拉晶型i的制备方法
|
JP5992054B2
(ja)
|
2011-11-29 |
2016-09-14 |
ノバルティス アーゲー |
ピラゾロピロリジン化合物
|
US9408885B2
(en)
|
2011-12-01 |
2016-08-09 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
JO3398B1
(ar)
|
2011-12-22 |
2019-10-20 |
Novartis Ag |
مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي
|
EP2794594A1
(en)
|
2011-12-22 |
2014-10-29 |
Novartis AG |
Quinoline derivatives
|
WO2013096051A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
AU2012355619A1
(en)
|
2011-12-23 |
2014-07-17 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
WO2013096060A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
US9126979B2
(en)
|
2011-12-23 |
2015-09-08 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
MX2014007729A
(es)
|
2011-12-23 |
2015-01-12 |
Novartis Ag |
Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
|
CN104136410A
(zh)
*
|
2011-12-29 |
2014-11-05 |
药品循环公司 |
作为组蛋白脱乙酰酶8抑制剂的肉桂酸羟基酰胺
|
RU2666530C2
(ru)
|
2012-01-12 |
2018-09-11 |
Йейл Юниверсити |
Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы
|
JO3357B1
(ar)
|
2012-01-26 |
2019-03-13 |
Novartis Ag |
مركبات إيميدازوبيروليدينون
|
TWI573792B
(zh)
*
|
2012-02-01 |
2017-03-11 |
歐陸斯迪公司 |
新穎治療劑
|
WO2013149581A1
(en)
|
2012-04-03 |
2013-10-10 |
Novartis Ag |
Combination products with tyrosine kinase inhibitors and their use
|
ES2646777T3
(es)
|
2012-05-15 |
2017-12-15 |
Novartis Ag |
Derivados de pirimidina, piridina y pirazina amida sustituidos con tiazol o imidazol y compuestos relacionados como inhibidores de ABL1, ABL2 y BCR-ABL1 para el tratamiento del cáncer, infecciones víricas específicas y trastornos específicos del CNS
|
CN104379574B
(zh)
|
2012-05-15 |
2017-03-01 |
诺华股份有限公司 |
用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物
|
PT2861579T
(pt)
|
2012-05-15 |
2018-04-27 |
Novartis Ag |
Derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl
|
EP2861576B1
(en)
|
2012-05-15 |
2018-01-10 |
Novartis AG |
Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
|
JP6171003B2
(ja)
|
2012-05-24 |
2017-07-26 |
ノバルティス アーゲー |
ピロロピロリジノン化合物
|
EP2861256B1
(en)
|
2012-06-15 |
2019-10-23 |
The Brigham and Women's Hospital, Inc. |
Compositions for treating cancer and methods for making the same
|
TW201408628A
(zh)
|
2012-07-16 |
2014-03-01 |
Chdi Foundation Inc |
組蛋白去乙醯酶抑制劑及組成物,暨其使用之方法
|
US9738643B2
(en)
|
2012-08-06 |
2017-08-22 |
Duke University |
Substituted indazoles for targeting Hsp90
|
MD20150043A2
(ro)
|
2012-10-02 |
2015-08-31 |
Epitherapeutics Aps |
Inhibitori ai histon-demetilazelor
|
SI2914254T1
(sl)
|
2012-10-30 |
2020-07-31 |
Mei Pharma, Inc. |
Kombinacija terapij za zdravljenje kemorezistentnih rakov
|
AU2013337247B2
(en)
|
2012-11-05 |
2018-08-09 |
Dana-Farber Cancer Institute, Inc. |
XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
|
JP2015536964A
(ja)
|
2012-11-08 |
2015-12-24 |
ノバルティス アーゲー |
B−raf阻害剤とヒストン脱アセチル化酵素阻害剤を含む医薬組合せおよび増殖性疾患の治療におけるそれらの使用
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫-吡啶并-□衍生物之固體形式
|
US9556180B2
(en)
|
2013-01-22 |
2017-01-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
|
WO2014115077A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Substituted purinone compounds
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
PE20151667A1
(es)
|
2013-02-27 |
2015-11-27 |
Epitherapeutics Aps |
Inhibidores de histona desmetilasas
|
CN105246482A
(zh)
|
2013-03-15 |
2016-01-13 |
因特利凯有限责任公司 |
激酶抑制剂的组合及其用途
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
KR20160061911A
(ko)
|
2013-04-08 |
2016-06-01 |
데니스 엠. 브라운 |
최적하 투여된 화학 화합물의 치료 효과
|
EA201591931A1
(ru)
|
2013-04-09 |
2016-05-31 |
Ликсте Байотекнолоджи, Инк. |
Композиции оксабициклогептанов и оксабициклогептенов
|
PT2991982T
(pt)
|
2013-04-29 |
2018-11-28 |
Chong Kun Dang Pharmaceutical Corp |
Novos compostos para inibidores seletivos de histonadesacetilase e composição farmacêutica que os compreende
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
KR20160099081A
(ko)
|
2013-07-26 |
2016-08-19 |
업데이트 파마 인코포레이트 |
비산트렌의 치료 효과 개선용 조합 방법
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
CA2920059A1
(en)
|
2013-09-22 |
2015-03-26 |
Calitor Sciences, Llc |
Substituted aminopyrimidine compounds and methods of use
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
CN103467359B
(zh)
*
|
2013-09-27 |
2015-04-22 |
山东大学 |
一种含有吲哚的肉桂酰胺类组蛋白去乙酰化酶抑制剂及其制备方法和应用
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
CN103664734B
(zh)
*
|
2013-12-10 |
2015-09-23 |
广州康缔安生物科技有限公司 |
杂环羟肟酸类化合物及其药用组合物和应用
|
WO2015087151A1
(en)
|
2013-12-12 |
2015-06-18 |
Chong Kun Dang Pharmaceutical Corp. |
Novel azaindole derivatives as selective histone deacetylase (hdac) inhibitors and pharmaceutical compositions comprising the same
|
KR101685639B1
(ko)
|
2014-01-03 |
2016-12-12 |
주식회사 종근당 |
신규한 인돌 유도체 화합물 및 이를 포함하는 약제학적 조성물
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
AU2015222865B2
(en)
|
2014-02-28 |
2019-06-20 |
Takeda Pharmaceutical Company Limited |
TYK2 inhibitors and uses thereof
|
US10000469B2
(en)
|
2014-03-25 |
2018-06-19 |
Duke University |
Heat shock protein 70 (hsp-70) receptor ligands
|
US9399637B2
(en)
|
2014-03-28 |
2016-07-26 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
EP3126345A1
(en)
|
2014-03-31 |
2017-02-08 |
Gilead Sciences, Inc. |
Inhibitors of histone demethylases
|
WO2015153345A1
(en)
|
2014-04-03 |
2015-10-08 |
Invictus Oncology Pvt. Ltd. |
Supramolecular combinatorial therapeutics
|
WO2015160845A2
(en)
|
2014-04-14 |
2015-10-22 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
GB201409488D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
GB201409485D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
GB201409471D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
WO2016016822A1
(en)
|
2014-07-31 |
2016-02-04 |
Novartis Ag |
Combination therapy
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
JP6749890B2
(ja)
|
2014-08-12 |
2020-09-02 |
モナッシュ ユニバーシティ |
リンパ指向プロドラッグ
|
SG11201701182VA
(en)
|
2014-08-27 |
2017-03-30 |
Gilead Sciences Inc |
Compounds and methods for inhibiting histone demethylases
|
EP2995630A1
(en)
|
2014-09-09 |
2016-03-16 |
Dublin Institute of Technology |
Hybrid compounds formed from ionic liquids and uses thereof in ion selective electrodes
|
CN107206071A
(zh)
|
2014-09-13 |
2017-09-26 |
诺华股份有限公司 |
Alk抑制剂的联合疗法
|
US20170209574A1
(en)
|
2014-10-03 |
2017-07-27 |
Novartis Ag |
Combination therapies
|
TWI744225B
(zh)
|
2015-02-27 |
2021-11-01 |
美商林伯士拉克許米公司 |
酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
|
MY190404A
(en)
|
2015-03-10 |
2022-04-21 |
Aduro Biotech Inc |
Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
|
US9745253B2
(en)
|
2015-03-13 |
2017-08-29 |
Forma Therapeutics, Inc. |
Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
|
NZ736015A
(en)
|
2015-05-22 |
2019-04-26 |
Chong Kun Dang Pharmaceutical Corp |
Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
WO2017004133A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
AU2016301196B2
(en)
|
2015-08-06 |
2022-09-08 |
Dana-Farber Cancer Institute, Inc. |
Tunable endogenous protein degradation
|
WO2017032281A1
(zh)
*
|
2015-08-21 |
2017-03-02 |
苏州晶云药物科技有限公司 |
帕比司他乳酸盐的新晶型
|
TWI707852B
(zh)
|
2015-09-02 |
2020-10-21 |
美商林伯士拉克許米公司 |
Tyk2 抑制劑及其用途
|
US11738087B2
(en)
|
2015-09-08 |
2023-08-29 |
Monash University |
Lymph directing prodrugs
|
WO2017044434A1
(en)
|
2015-09-11 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
KR20180072704A
(ko)
|
2015-10-23 |
2018-06-29 |
나비토르 파마슈티칼스 인코포레이티드 |
세스트린-gator2 상호작용의 조절제 및 이의 용도
|
EP3370715A4
(en)
|
2015-11-02 |
2019-05-15 |
Yale University |
CHIMERIC COMPOUNDS PROVIDED AGAINST PROTEOLYSIS AND METHOD FOR THE PRODUCTION AND USE THEREOF
|
ITUB20155193A1
(it)
|
2015-11-03 |
2017-05-03 |
Italfarmaco Spa |
Sospensioni orali di Givinostat fisicamente e chimicamente stabili
|
US11357742B2
(en)
|
2015-12-14 |
2022-06-14 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
WO2017106328A1
(en)
|
2015-12-14 |
2017-06-22 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
WO2017106352A1
(en)
|
2015-12-14 |
2017-06-22 |
Raze Therapeutics, Inc. |
Caffeine inhibitors of mthfd2 and uses thereof
|
US10610527B2
(en)
|
2015-12-22 |
2020-04-07 |
X4 Pharmaceuticals, Inc. |
Methods for treating immunodeficiency disease
|
CN105732467A
(zh)
*
|
2016-01-13 |
2016-07-06 |
深圳市康立生生物科技有限公司 |
一种panobinostat(帕比司他)的制备方法
|
PL3426244T3
(pl)
|
2016-03-09 |
2023-09-25 |
Raze Therapeutics, Inc. |
Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania
|
WO2017156165A1
(en)
|
2016-03-09 |
2017-09-14 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
WO2017157813A1
(en)
|
2016-03-15 |
2017-09-21 |
F. Hoffmann-La Roche Ag |
Combinations of lsd1 inhibitors for the treatment of hematological malignancies
|
AU2017233898B2
(en)
|
2016-03-15 |
2022-12-15 |
Oryzon Genomics, S.A. |
Combinations of LSD1 inhibitors for use in the treatment of solid tumors
|
JP2019510785A
(ja)
|
2016-04-08 |
2019-04-18 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
癌を処置する方法
|
WO2017184956A1
(en)
|
2016-04-22 |
2017-10-26 |
Duke University |
Compounds and methods for targeting hsp90
|
AR108257A1
(es)
|
2016-05-02 |
2018-08-01 |
Mei Pharma Inc |
Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
|
EP3455218A4
(en)
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
|
CN109562113A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的螺环降解决定子体
|
CN109562107A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的杂环降解决定子体
|
CA3027495A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
EP3472129A4
(en)
|
2016-06-21 |
2019-12-04 |
X4 Pharmaceuticals, Inc. |
CXCR4 INHIBITORS AND USES THEREOF
|
EP3484858A4
(en)
*
|
2016-06-21 |
2020-02-26 |
The University of Melbourne |
HIV LATENCY ACTIVATORS
|
CN109562106B
(zh)
|
2016-06-21 |
2023-03-21 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
WO2018015493A1
(en)
|
2016-07-20 |
2018-01-25 |
Royal College Of Surgeons In Ireland |
Metal complexes having therapeutic applications
|
WO2018039205A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating breast cancer
|
WO2018039203A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating multiple myeloma
|
WO2018054960A1
(en)
|
2016-09-21 |
2018-03-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting and treating resistance to chemotherapy in npm-alk(+) alcl
|
US10927083B2
(en)
|
2016-09-29 |
2021-02-23 |
Duke University |
Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
|
US10207998B2
(en)
|
2016-09-29 |
2019-02-19 |
Duke University |
Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
|
AU2016426574B2
(en)
|
2016-10-11 |
2023-07-13 |
Euro-Celtique S.A. |
Hodgkin lymphoma therapy
|
CA3039202A1
(en)
|
2016-10-14 |
2018-04-19 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
AU2017345736B2
(en)
|
2016-10-21 |
2022-04-07 |
Takeda Pharmaceutical Company Limited |
TYK2 inhibitors and uses thereof
|
US10414727B2
(en)
|
2016-11-08 |
2019-09-17 |
Navitor Pharmaceuticals, Inc. |
Phenyl amino piperidine mTORC inhibitors and uses thereof
|
WO2018102397A1
(en)
|
2016-11-29 |
2018-06-07 |
PureTech Health LLC |
Exosomes for delivery of therapeutic agents
|
US11091451B2
(en)
|
2016-12-05 |
2021-08-17 |
Raze Therapeutics, Inc. |
SHMT inhibitors and uses thereof
|
US11730819B2
(en)
|
2016-12-23 |
2023-08-22 |
Bicycletx Limited |
Peptide derivatives having novel linkage structures
|
WO2018127699A1
(en)
|
2017-01-06 |
2018-07-12 |
Bicyclerd Limited |
Compounds for treating cancer
|
JP7227912B2
(ja)
|
2017-02-08 |
2023-02-24 |
ダナ-ファーバー キャンサー インスティテュート,インコーポレイテッド |
キメラ抗原受容体の調節
|
AU2018230737B2
(en)
|
2017-03-08 |
2022-09-22 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors, uses, and methods for production thereof
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
WO2018191146A1
(en)
|
2017-04-10 |
2018-10-18 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl rheb inhibitors and uses thereof
|
JOP20180036A1
(ar)
|
2017-04-18 |
2019-01-30 |
Vifor Int Ag |
أملاح لمثبطات فروبورتين جديدة
|
WO2018197893A1
(en)
|
2017-04-27 |
2018-11-01 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
CN107141244B
(zh)
*
|
2017-05-08 |
2019-11-19 |
潍坊医学院 |
吲哚丁酸类组蛋白去乙酰酶抑制剂及其制备方法和应用
|
GB201709402D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating t-pll
|
GB201709406D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro-Cletique S A |
Compounds for treating TNBC
|
GB201709403D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating sarcoma
|
GB201709405D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating ovarian cancer
|
JP7301757B2
(ja)
|
2017-06-26 |
2023-07-03 |
バイスクルアールディー・リミテッド |
検出可能部分を持つ二環式ペプチドリガンドおよびその使用
|
CN117946114A
(zh)
|
2017-07-28 |
2024-04-30 |
武田药品工业株式会社 |
Tyk2抑制剂与其用途
|
KR101977970B1
(ko)
|
2017-08-04 |
2019-05-14 |
중원대학교 산학협력단 |
신규한 벤즈아미드계 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 예방 또는 치료용 약학 조성물
|
US20200283482A1
(en)
|
2017-08-14 |
2020-09-10 |
Bicyclerd Limited |
Bicyclic peptide ligand prr-a conjugates and uses thereof
|
US20200291096A1
(en)
|
2017-08-14 |
2020-09-17 |
Bicyclerd Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
EP3684366A4
(en)
|
2017-09-22 |
2021-09-08 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES OF THE LATEST
|
IL273432B
(en)
|
2017-09-22 |
2022-09-01 |
Kymera Therapeutics Inc |
Protein compounds and their uses
|
EP3461480A1
(en)
|
2017-09-27 |
2019-04-03 |
Onxeo |
Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
|
EP3461488A1
(en)
|
2017-09-27 |
2019-04-03 |
Onxeo |
Combination of a dbait molecule and a hdac inhibitor for treating cancer
|
CA3079422A1
(en)
|
2017-10-24 |
2019-05-02 |
Oncopep, Inc. |
Peptide vaccines and pembrolizumab for treating breast cancer
|
WO2019084026A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE
|
WO2019083960A1
(en)
|
2017-10-24 |
2019-05-02 |
Oncopep, Inc. |
PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
|
WO2019084030A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
|
EP3710006A4
(en)
|
2017-11-19 |
2021-09-01 |
Sunshine Lake Pharma Co., Ltd. |
SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE
|
US10537585B2
(en)
|
2017-12-18 |
2020-01-21 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising dexamethasone
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
AU2017444054B2
(en)
|
2017-12-21 |
2021-10-07 |
Hefei Institutes Of Physical Science, Chinese Academy Of Sciences |
Class of pyrimidine derivative kinase inhibitors
|
SG11202005912PA
(en)
|
2017-12-26 |
2020-07-29 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
US11485743B2
(en)
|
2018-01-12 |
2022-11-01 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
US10751339B2
(en)
|
2018-01-20 |
2020-08-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
CN111867581B
(zh)
|
2018-01-29 |
2023-12-26 |
默克专利股份有限公司 |
Gcn2抑制剂及其用途
|
TWI816742B
(zh)
|
2018-01-29 |
2023-10-01 |
美商維泰克斯製藥公司 |
Gcn2抑制劑及其用途
|
JP7362667B2
(ja)
|
2018-02-12 |
2023-10-17 |
イニミューン・コーポレーション |
Toll様受容体リガンド
|
EA202091742A1
(ru)
|
2018-02-27 |
2021-02-19 |
Артакс Биофарма Инк. |
ПРОИЗВОДНЫЕ ХРОМЕНА В КАЧЕСТВЕ ИНГИБИТОРОВ ВЗАИМОДЕЙСТВИЯ TCR-Nck
|
WO2019183523A1
(en)
|
2018-03-23 |
2019-09-26 |
Genentech, Inc. |
Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
|
AU2019251223A1
(en)
|
2018-04-13 |
2020-11-26 |
Arvinas Operations, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
IL278122B2
(en)
|
2018-04-24 |
2024-01-01 |
Vertex Pharma |
Petridinon compounds and their uses
|
SI3784666T1
(sl)
|
2018-04-24 |
2022-07-29 |
Merck Patent Gmbh |
Antiproliferacijske spojine in njihove uporabe
|
WO2019238886A1
(en)
|
2018-06-13 |
2019-12-19 |
University Of Dundee |
Bifunctional molecules for targeting usp14
|
US11925690B2
(en)
|
2018-06-13 |
2024-03-12 |
Amphista Therapeutics Limited |
Bifunctional molecules for targeting Rpn11
|
KR20210020107A
(ko)
|
2018-06-13 |
2021-02-23 |
암피스타 테라퓨틱스 엘티디 |
UchL5 표적화를 위한 이중작용성 분자
|
CN112423843B
(zh)
|
2018-06-15 |
2023-11-28 |
詹森药业有限公司 |
雷帕霉素类似物和其用途
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
CN108752255A
(zh)
*
|
2018-07-19 |
2018-11-06 |
重庆医科大学 |
一种帕比司他及其关键中间体的制备方法
|
EP3826988A4
(en)
|
2018-07-24 |
2023-03-22 |
Hygia Pharmaceuticals, LLC |
COMPOUNDS, DERIVATIVES AND ANALOGS AGAINST CANCER
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
EP3846793B1
(en)
|
2018-09-07 |
2024-01-24 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
EP3866789A4
(en)
|
2018-10-15 |
2022-07-06 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND USES THEREOF
|
EP3870597A1
(en)
|
2018-10-23 |
2021-09-01 |
BicycleTx Limited |
Bicyclic peptide ligands and uses thereof
|
CN109574936B
(zh)
*
|
2018-11-23 |
2022-02-22 |
沈阳药科大学 |
一种具有hdac6抑制活性的异羟肟酸类化合物及其应用
|
US11352350B2
(en)
|
2018-11-30 |
2022-06-07 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
WO2020112937A1
(en)
|
2018-11-30 |
2020-06-04 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
EP3897631A4
(en)
|
2018-12-20 |
2022-11-23 |
C4 Therapeutics, Inc. |
TARGETED PROTEIN DEGRADATION
|
JP2022518505A
(ja)
|
2019-01-23 |
2022-03-15 |
ニンバス ラクシュミ, インコーポレイテッド |
Tyk2阻害剤およびその使用
|
WO2020165600A1
(en)
|
2019-02-14 |
2020-08-20 |
Bicycletx Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
AU2020253990A1
(en)
|
2019-04-02 |
2021-10-28 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
MA55565A
(fr)
|
2019-04-05 |
2022-02-09 |
Kymera Therapeutics Inc |
Agents de dégradation de stat et leurs utilisations
|
CN114502540A
(zh)
|
2019-05-31 |
2022-05-13 |
医肯纳肿瘤学公司 |
Tead抑制剂和其用途
|
GB201913121D0
(en)
|
2019-09-11 |
2019-10-23 |
Seald As |
Compositions and methods for treatment of cholangiocarcinoma
|
GB201913123D0
(en)
|
2019-09-11 |
2019-10-23 |
Seald As |
Compositions and methods for treatment of cholangiocarcinoma
|
GB201913124D0
(en)
|
2019-09-11 |
2019-10-23 |
Seald As |
Compositions and methods for treatment of cholangiocarcinoma
|
GB201913122D0
(en)
|
2019-09-11 |
2019-10-23 |
Seald As |
Compositions and methods for treatment of cholangiocarcinoma
|
EP4028385A4
(en)
|
2019-09-11 |
2023-11-08 |
Vincere Biosciences, Inc. |
USP30 INHIBITORS AND USES THEREOF
|
EP3798250A1
(en)
|
2019-09-25 |
2021-03-31 |
University College Dublin |
Hyperbranched cationic polymers useful as nucleic acid delivery vectors for transfecting
|
US20220340933A1
(en)
|
2019-09-25 |
2022-10-27 |
University College Dublin |
Nanoparticle compositions for gene therapy
|
EP4054546A4
(en)
*
|
2019-11-06 |
2023-10-18 |
Dana-Farber Cancer Institute, Inc. |
SELECTIVE HISTONE DEACETYLASE (HDAC) DEGRADATION PRODUCTS AND METHOD FOR THE USE THEREOF
|
CA3163680A1
(en)
|
2019-12-05 |
2021-06-10 |
David John O'neill |
Rapamycin analogs and uses thereof
|
BR112022011651A2
(pt)
|
2019-12-17 |
2022-08-23 |
Kymera Therapeutics Inc |
Degradadores de irak e usos dos mesmos
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
WO2021127443A1
(en)
|
2019-12-19 |
2021-06-24 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
TW202136242A
(zh)
|
2019-12-23 |
2021-10-01 |
美商凱麥拉醫療公司 |
Smarca降解劑及其用途
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
US20210268115A1
(en)
|
2020-02-05 |
2021-09-02 |
Puretech Lyt, Inc. |
Lipid prodrugs of neurosteroids
|
IT202000004075A1
(it)
|
2020-02-27 |
2021-08-27 |
Flamma Spa |
Processo per la preparazione di panobinostat
|
AU2021230289A1
(en)
|
2020-03-03 |
2022-09-29 |
PIC Therapeutics, Inc. |
eIF4E inhibitors and uses thereof
|
WO2021185844A1
(en)
|
2020-03-16 |
2021-09-23 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
WO2021233534A1
(en)
|
2020-05-20 |
2021-11-25 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
JP2023518423A
(ja)
|
2020-03-19 |
2023-05-01 |
カイメラ セラピューティクス, インコーポレイテッド |
Mdm2分解剤およびそれらの使用
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
US20230285576A1
(en)
|
2020-08-05 |
2023-09-14 |
Ellipses Pharma Ltd |
Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
|
KR20230074721A
(ko)
|
2020-08-17 |
2023-05-31 |
바이사이클티엑스 리미티드 |
Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
IL303376A
(en)
|
2020-12-02 |
2023-08-01 |
Ikena Oncology Inc |
TEAD inhibitors and their uses
|
PE20240545A1
(es)
|
2020-12-18 |
2024-03-19 |
Amphista Therapeutics Ltd |
Moleculas bifuncionales novedosas para la degradacion de proteinas dirigidas
|
GB202020359D0
(en)
|
2020-12-22 |
2021-02-03 |
Midatech Pharma Wales Ltd |
Pharmaceutical compositions and use thereof in combination therapy for brain cancer
|
AU2022216810A1
(en)
|
2021-02-02 |
2023-08-24 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
MX2023009059A
(es)
|
2021-02-02 |
2023-09-15 |
Liminal Biosciences Ltd |
Antagonistas de gpr84 y usos de estos.
|
EP4323066A1
(en)
|
2021-04-16 |
2024-02-21 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023028235A1
(en)
|
2021-08-25 |
2023-03-02 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
US20230134932A1
(en)
|
2021-08-25 |
2023-05-04 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
WO2023041805A1
(en)
|
2021-09-20 |
2023-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
|
GB2611043A
(en)
|
2021-09-22 |
2023-03-29 |
Univ Dublin City |
A cis-platinum(II)-oligomer hybrid
|
WO2023089183A1
(en)
|
2021-11-19 |
2023-05-25 |
Branca Bunus Limited |
A composition comprising a therapeutically active agent packaged within a drug delivery vehicle
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023194441A1
(en)
|
2022-04-05 |
2023-10-12 |
Istituto Nazionale Tumori Irccs - Fondazione G. Pascale |
Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
GB2617409A
(en)
|
2022-04-27 |
2023-10-11 |
Cancertain Ltd |
Method for predicting responsiveness to therapy
|
WO2023230205A1
(en)
|
2022-05-25 |
2023-11-30 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023242597A1
(en)
|
2022-06-16 |
2023-12-21 |
Amphista Therapeutics Limited |
Bifunctional molecules for targeted protein degradation
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
WO2024030441A1
(en)
|
2022-08-02 |
2024-02-08 |
National University Corporation Hokkaido University |
Methods of improving cellular therapy with organelle complexes
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
WO2024028363A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
WO2024041744A1
(en)
|
2022-08-26 |
2024-02-29 |
Biodexa Ltd. |
Combination therapy for brain cancer
|